This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them see our Privacy.



Collaboration across borders to unleash the potential of our pipeline assets

Our BD&L team, formed by professionals with years of business development experience, is responsible for initiating various partnerships. Currently, our in-licensing efforts are focused on Endocrine, Metabolic and Cardiovascular Disorders, with a special emphasis on Women’s Health, to synergize with HopeMed’s scientific expertise and broad clinical network.


Current Collaborators

  • 1-319.png


    Hope Medicine entered into a global license agreement with Bayer to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor in 2019.

  • kongbai.png

    Nanjing JiangBei New Area

    With the strong support and help from the Nanjing JiangBei New Area, Hope Medicine (Nanjing) Co., Ltd. was founded and registered in JiangBei, and the Biological R&D center of the company was officially launched in Nanjing Bio-tech and Pharmaceutical Valley of JiangBei New Area in October 2021.

  • 4.png

    Peking University

    Hope Medicine has established a diversified research portfolio based on the founder, Professor Xiao's breakthrough research at the Institute of Molecular Medicine (IMM) at Peking University via a joint research lab, with a strong translational focus, for a continuous innovative early discovery pipeline.

  • 2.png

    Lonza (GZB)

    Lonza Guangzhou facility (GZB) supports HMI-115 Drug Substance process tech transfer and clinical supply for HopeMed Ph1/2 global MRCT.

  • 1-34.png

    WuXi Biologics

    Manufactures HMI115 Drug Product and Placebo to support HopeMed Ph1/2 global MRCT.

  • 5.png


    HopeMedicine entered a collaboration with Parexel, one of the world's leading global clinical research organizations (CRO), to support global clinical study of HMI-115.

  • 1.png


    Hope Medicine entered collaborations with dMed-Clinipace for clinical development of HMI-115 in Asia Pacific region.

Follow Us